



French Expert to Present Results from Dicot Pharma at ESSM

Uppsala, Sweden, December 17, 2024. Results from Dicot Pharma's recent clinical trial have been selected for presentation at the European Society for Sexual Medicine's annual congress. Professor François Giuliano, a urologist and specialist in male sexual health, will deliver a podium presentation on the findings from the company's phase 1 clinical study as well as the study design for its ongoing phase 2a study, in which he serves as a medical expert.

The European Society for Sexual Medicine (ESSM) is Europe's leading scientific organization in sexual medicine. Its annual conference gathers prominent researchers and clinicians from around the globe. This time, experts will convene at the historic University of Vienna, February 20–22, 2025.

The potency drug developer Dicot Pharma completed its phase 1 study earlier this year. Exploratory results from the study of the candidate LIB-01 revealed a clear efficacy signal, with one dose group demonstrating clinically relevant and statistically significant improvement in erectile function. Also notable was the duration of LIB-01's effect – four weeks after dosing.

The company is now conducting its phase 2a study, with Professor François Giuliano as its medical expert. Professor Giuliano is a renowned urologist specializing in male sexual health, and the former president of ESSM.

“The results shown by Dicot Pharma are unique. The efficacy signal observed in the phase 1 study, with improved erectile function lasting four weeks, has never been reported for a drug targeting erectile dysfunction. LIB-01 has the potential to become a game changer in the landscape of the medical treatment for erectile dysfunction. Sharing this with the European medical community and serving as the medical expert for Dicot Pharma's Phase 2a study is very exciting,” says Professor Giuliano.

For further information, please contact:

Elin Trampe, CEO

Phone: +46 72 502 10 10

E-mail: elin.trampe@dicotpharma.com

About Dicot Pharma AB

Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma's strategy is to develop LIB-01 under own auspices until phase 2a study and thereafter in partnership with larger, established pharmaceutical companies, finance

and develop LIB-01 further to a registered pharmaceutical on the world market.

Dicot Pharma is listed on Nasdaq First North and has approximately 7,900 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit www.dicotpharma.com.

This is a translation from the Swedish original. In case of differences between versions, the Swedish version prevails.